stockrowPrestige Consumer Healthcare Inc.
PBH Healthcare Drug Manufacturers Specialty & Generic
Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025.
- Revenue
- +22.7%
- EPS
- −38.4%
- Free cash flow
- −38.2%
- Total debt
- +100.9%
Quarter to September 2026, against a year earlier
Follow PBH
Alert me
Prestige Consumer Healthcare Inc. (PBH) EPS (diluted)
Prestige Consumer Healthcare Inc.'s EPS (diluted) for fiscal 2026 was $3.91, down 8.86% from $4.29 in fiscal 2025. Over the twelve months to 30 September 2026 it was $3.24. Over the past ten years it has ranged from −$1.65 (fiscal 2023) to $6.34 (fiscal 2018); the current reading is higher than 67% of that period. Prestige Consumer Healthcare Inc. ranks 7th of 75 Drug Manufacturers Specialty & Generic companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2026 | $3.91 | (8.86%) |
| FY2025 | $4.29 | 2.88% |
| FY2024 | $4.17 | — |
| FY2023 | −$1.65 | — |
| FY2022 | $4.04 | 24.31% |
| FY2021 | $3.25 | 16.91% |
| FY2020 | $2.78 | — |
| FY2019 | −$0.69 | — |
| FY2018 | $6.34 | 387.69% |
| FY2017 | $1.30 | (30.85%) |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.53 | (13.11%) |
| Jun 2026 | $0.61 | (46.02%) |
| Mar 2026 | $1.13 | 16.49% |
| Dec 2025 | $0.97 | 12.79% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| PBH Prestige Consumer Healthcare Inc. | $3.24 |
| XERS Xeris Biopharma Holdings, Inc. compare | −$0.05 |
| ALVO Alvotech compare | −$1.24 |
| BCRX BioCryst Pharmaceuticals, Inc. compare | −$1.42 |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −$1.43 |
| TRLV Trulieve Cannabis Corp. compare | −$2.47 |
| PRGO Perrigo Company plc compare | −$12.76 |
| RGC Regencell Bioscience Holdings Limited compare | — |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | — |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on PBH
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement